Biogaia AB is a renowned company in the field of microbiome research and development. With a strong focus on innovation, Biogaia AB stands for excellence, integrity, and sustainability. The company's core values include maintaining high-quality standards, fostering scientific collaboration, and promoting a healthy microbiome for individuals worldwide. Biogaia AB's corporate philosophy is centered around providing evidence-based probiotics to improve health and well-being. By combining cutting-edge research, stringent quality control measures, and a commitment to sustainability, Biogaia AB has established itself as a leader in the probiotics industry.

Biogaia AB is primarily present in various countries and regions worldwide. Some of the key locations where Biogaia AB operates include Sweden, its home country, as well as other Nordic countries such as Norway, Denmark, Finland, and Iceland. Additionally, Biogaia AB has a significant presence in several European markets, including Germany, France, Italy, Spain, and the United Kingdom. The company has also expanded its reach to other parts of the world, including the United States, Canada, Australia, and several countries in Asia such as China, Japan, South Korea, and India.

Some significant milestones achieved by Biogaia AB include the development of innovative probiotic products, successful commercialization of these products in over 100 countries worldwide, and establishment of partnerships with various healthcare organizations. Biogaia AB has also received regulatory approvals for its probiotic solutions, paving the way for widespread use and adoption. The company has consistently demonstrated strong financial performance, exceeding market expectations and driving sustained growth. With a strong focus on research and development, Biogaia AB continues to expand its product portfolio and explore new applications for its probiotic technology, further strengthening its position in the global market.

Biogaia AB is a Swedish healthcare company that specializes in developing and selling probiotic products. Established in 1990, the company has a lengthy history of expertise in the field. Biogaia AB focuses on research, innovation, and producing high-quality probiotic solutions for individuals of all ages. With a global presence, the company is committed to improving health and well-being worldwide through its range of products. Biogaia AB's dedication to scientific advancements and its mission to provide effective and safe probiotic solutions has solidified its reputation as a leading player in the healthcare industry.

The main competitors of Biogaia AB in the market include Nestlé, Procter & Gamble, Chr. Hansen Holding A/S, and Yakult Honsha Co., Ltd.

Biogaia AB is primarily active in the pharmaceutical and healthcare industries.

The business model of Biogaia AB focuses on developing, producing, and selling probiotic products. Biogaia specializes in probiotics, which are live bacteria and yeasts that are beneficial for health. The company offers various probiotic solutions targeting different areas such as gut health, oral health, and infant health. Biogaia's products are available in the form of drops, tablets, or chewable tablets, making them convenient for consumers. The company's business model centers around research and development to continuously innovate and improve their probiotic offerings. Biogaia AB aims to provide high-quality probiotic products to enhance overall well-being.

Biogaia KGV ir 33,58.

Biogaia KUV ir 8,08.

AlleAktien kvalitātes vērtējums Biogaia ir 6/10.

gaidāmā Biogaia apgrozījums ir 1,47 miljardi SEK.

gaidāmā Biogaia peļņa ir 353,36 milj. SEK.

Biogaia AB is a Swedish company specializing in the development, production, and marketing of probiotic products. The company was founded in 1990 and is headquartered in Stockholm. Biogaia operates in over 100 countries worldwide and employs over 200 employees. The company's business model is based on three main divisions: Human Health, Health Products for Animals, and Partner Products. The Human Health division is the largest division of the company and includes all products intended for human consumption. The range includes various probiotic dietary supplements, beverages, and foods, all aimed at improving the gut microbiome and promoting overall well-being. An example of a product from this division is BioGaia Protectis Drops, a probiotic dietary supplement for babies and toddlers. The product contains the probiotic strain Lactobacillus reuteri Protectis and is recommended for strengthening immune defense and preventing gastrointestinal complaints. Health products for animals include products for pets such as dogs and cats. The range includes probiotic supplements as well as care and health products. An example of a product from this division is BioGaia ProTectis Drops for dogs, which contributes to supporting the immune system and gastrointestinal functions. In the field of partner products, Biogaia collaborates with other companies to offer probiotic products in combination with their own products. An example of this is the partnership with Nestlé Health Science to develop products for the immune system and gut for adults and children. Biogaia's business model is based on the research and development of probiotic products. The company has worked closely with various universities and research institutions to develop new products and gain scientific insights into the effects of probiotics. Biogaia has filed over 200 patents for different probiotic strains, making it a leader in the industry. In addition to research and development, Biogaia also has a strong presence in the marketing and distribution of its products. The company utilizes the latest technologies and marketing strategies to sell its products worldwide. It collaborates closely with retailers, pharmacies, and other distribution partners to bring its products to the market. Overall, Biogaia's business model is focused on the development and marketing of probiotic products. The company has a strong presence in various industries tailored to the needs of customers, especially in the health and well-being sector. Biogaia's continuous research and development enable it to offer innovative products that can contribute to improving the quality of life for people and animals.

Biogaia izmaksā dividendes 0,73 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Biogaia vai uzņēmums nedod dividendes.

Biogaia ISIN ir SE0000470395.

Biogaia WKN ir 914755.

Biogaia simbols ir BIOG B.ST.

Pēdējo 12 mēnešu laikā Biogaia maksāja dividendes 1,45 SEK apmērā. Tas atbilst aptuveni 1,23 % dividendes ražībai. Nākamajos 12 mēnešos Biogaia plāno maksāt dividendes 1,59 SEK apmērā.

Biogaia pašreizējā dividendu rentabilitāte ir 1,23 %.

Biogaia maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos jūnijs, jūnijs, jūnijs, jūnijs.

Biogaia pēdējo 12 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,59 SEK. Tas atbilst dividendes ražībai 1,35 %.

Biogaia tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Biogaia apmērā 1,9 SEK, kas tika izmaksāta 15.05.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 8.05.2024..

Pēdējās dividendes izmaksa notika 15.05.2024..

Gadā 2023, Biogaia izmaksāja 0,726 SEK dividendes.

Biogaia dividendes tiek izmaksātas SEK.